Sequence‐specific recognition of the internalization motif of the Alzheimer's amyloid precursor protein by the X11 PTB domain by Zhang, Zhongtao et al.
The EMBO Journal Vol.16 No.20 pp.6141–6150, 1997
Sequence-specific recognition of the internalization
motif of the Alzheimer’s amyloid precursor protein
by the X11 PTB domain
Zhongtao Zhang, Chi-Hon Lee1,
Valsan Mandiyan, Jean-Paul Borg2,
Benjamin Margolis2, Joseph Schlessinger
and John Kuriyan1,3,4
Department of Pharmacology, New York University Medical Center,
550 First Avenue, New York, NY 10016, 1Laboratories of Molecular
Biophysics, 3Howard Hughes Medical Institute, The Rockefeller
University, 1230 York Avenue, New York, NY 10021 and
2Howard Hughes Medical Institute, Department of Internal Medicine
and Biological Chemistry, University of Michigan Medical School,
Ann Arbor, MI 48109, USA
4Corresponding author
Z.Zhang and C.-H.Lee contributed equally to this work
The crystal structure of the phosphotyrosine-binding
domain (PTB) of the X11 protein has been determined,
in complex with unphosphorylated peptides corres-
ponding to a region of β-amyloid precursor protein
(βAPP) that is required for receptor internalization.
The mode of binding to X11 of the unphosphorylated
peptides, which contain an NPxY motif, resembles that
of phosphorylated peptides bound to the Shc and IRS-1
PTB domains. Eight peptide residues make specific
contacts with the X11 PTB domain, and they collect-
ively achieve high affinity (KD  0.32 μM) and specifi-
city. These results suggest that, in contrast to the SH2
domains, the PTB domains are primarily peptide-
binding domains that have, in some cases, acquired
specificity for phosphorylated tyrosines.




(PTB/PI) domain was first identified as the component
of the adaptor protein Shc (Src homology 2/collagen
homology) that binds to activated and tyrosine-phosphoryl-
ated receptors (Blaikie et al., 1994; Kavanaugh and
Williams, 1994; Batzer et al., 1995b; Dikic et al., 1995;
Kavanaugh et al., 1995; Pratt et al., 1996; Ravichandran
et al., 1996). The interactions mediated by the PTB
domains are critical for tyrosine phosphorylation of Shc
and another adaptor protein, IRS-1 (insulin receptor sub-
strate-1) (Isakoff et al., 1996; Milia et al., 1996; O’Bryan
et al., 1996; Ravichandran et al., 1996; Sawka-Verhelle
et al., 1996); the phosphotyrosine-containing sequences
in Shc and IRS-1 in turn serve as docking sites for other
signaling molecules (Pelicci et al., 1996; White, 1996).
The architecture and peptide recognition mechanism of
the PTB domains are distinct from those of the SH2 (Src
homology 2) domains (Zhou et al., 1995b). While the
SH2 domains recognize the phosphotyrosine and peptide
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residues immediately C-terminal to it (Songyang et al.,
1993), the PTB domains (such as Shc and IRS-1) interact
with peptide residues that are N-terminal to the phospho-
tyrosine. In addition, a β-turn formed by the motif NPxY*
(N, Asn; P, Pro; x, any amino acid; Y*, phosphotyrosine)
is critical for recognition (Batzer et al., 1995b; Kavanaugh
et al., 1995; Zhou et al., 1995c).
The three-dimensional structures of the Shc (Zhou et al.,
1995b) and IRS-1 PTB domains (Eck et al., 1996) are
very similar, although they share no significant sequence
identity. Database searches for proteins homologous to
the Shc PTB domain have led to the identification of a
small number of novel PTB domains (Bork and Margolis,
1995). Of these, the X11 protein is a neuron-specific
protein of as yet unknown function that contains two PDZ
domains in addition to a PTB domain at its C-terminus
(Duclos et al., 1993; Borg et al., 1996). The X11 protein
has been found to bind to the cytoplasmic domain of the
β-amyloid precursor protein (β-APP) in vivo, via its PTB
domain (Borg et al., 1996; McLoughlin and Miller, 1996).
Although the biological consequence of this interaction is
unclear at present, the X11 PTB domain and β-APP
interact with each other with high affinity and high
specificity (Borg et al., 1996). β-APP appears to be the
major ligand for the X11 PTB domain in vivo (Borg et al.,
1996). In addition, the X11 PTB domain discriminates
against other potential PTB-binding proteins that contain
the NPxY motif; in contrast to the Shc or the IRS-1 PTB
domains, the X11 PTB domain does not interact with a
number of tested growth factor receptors in either the
activated or the resting states (J.-P.Borg and B.Margolis,
unpublished data).
Biochemical characterization of the X11/β-APP inter-
action indicated that a NPTY motif located at the
C-terminus of β-APP is essential for its association with
the X11 PTB domain (Borg et al., 1996). A 14 residue
unphosphorylated peptide (APP peptide) encompassing
the sequence QNGEYNPTYKFFEQ competes efficiently
with full-length β-APP in binding to the X11 PTB domain,
suggesting that this local sequence accounts for the bind-
ing. This region is also required for the internalization of
β-APP, a process that leads to the degradation of β-APP
and the formation of the pathological β-amyloid peptides
(Aβ) (Haass et al., 1993; Lai et al., 1995). Most interest-
ingly, the interaction between the X11 PTB domain and
β-APP (as well as APP peptides) appears to be independent
of phosphorylation (Borg et al., 1996). A phosphorylation-
independent interaction for Shc PTB (Charest et al., 1966)
and between β-APP and the FE65 PTB domain has also
been reported (Fiore et al., 1995; McLoughlin and Miller,
1996). The dispensability of phosphorylation for binding
distinguishes the PTB domains from the SH2 domains,
which strictly require their peptide targets to be tyrosine
phosphorylated.
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Table I. Binding affinities of APP peptides for X11 PTB domain
Peptidea Sequenceb KD(μM)c (r2)d Relative
affinity
14mer QNGYENPTYKFFEQ 0.32  0.03 0.981 1.0
E(–4)A QNGYANPTYKFFEQ 1.73  0.14 0.993 0.19
F(2)A QNGYENPTYKAFEQ 3.44  0.48 0.976 0.10
F(3)A QNGYENPTYKFAEQ 3.11  0.30 0.989 0.11
E(4)A QNGYENPTYKFFAQ 0.59  0.05 0.992 0.56
10mer GYENPTYKFF 4.56  0.70 0.963 0.07
10merP GYENPTY*KFF 8.26  1.71 0.932 0.04
aThe 10 residue (10mer) and 14 residue (14mer) APP peptides were
also used in the crystallographic study. Peptide residues are numbered
as follows in the 14mer peptide, with the 10mer peptide encompassing
residues –6 to 3:
Q N G Y E N P T Y K F F E Q
–8 –7 –6 –5 –4 –3 –2 –1 0 1 2 3 4 5
b* indicates that the tyrosine is phosphorylated.
cThe equlibrium dissociation constants, KD are determined by surface
plasmon resonance (SPR) competition assay (see Materials and
methods) and are averages of three independent experiments.
dr2 is the coefficient of determinants.
In an effort to understand the interaction between the
X11 PTB domain and the APP peptide we have determined
the three-dimensional structure of the X11 PTB domain
bound to the APP peptide and have carried out binding
assays. We found that unphosphorylated APP peptides
bind to the X11 PTB domain with affinities that are similar
to other PTB/phosphopeptide interactions. However, the
X11 PTB domain exhibits binding specificity that is
distinct from those of Shc and IRS-1 PTB domains. In
addition, the crystal structures of X11 PTB/APP peptide
complexes reveals that the sequence specific recognition
extends to peptide residues that are C-terminal to the
NPxY motif. The extensive interactions between the
unphosphorylated APP peptide and X11 PTB domain
highlights the role of these modules as general peptide
recognition domains.
Results
The binding of X11 PTB domain to APP peptide
Using surface plasmon resonance (SPR) analysis we
found that the X11 PTB domain binds strongly to both
phosphorylated and unphosphorylated APP peptides, with
less than a two-fold difference in their binding affinities
(Table I). The highest affinity (KD  0.32 μM) was
observed for a 14 residue unphosphorylated APP peptide
(see Materials and methods). For comparison, the KD for
the Shc PTB domain interacting with an 18 residue Trk-
derived phospho-peptide is 0.04 μM (Mandiyan et al.,
1996) and the KD for the IRS-1 PTB domain interacting
with a 11 residue phospho-peptide corresponding to a
region of the IL4 receptor is 6 μM (Zhou et al., 1996).
The on- and off-rates for the 14 residue unphosphorylated
APP peptide were also measured, and are comparable
with those of the Shc PTB/peptide interactions (Zhou
et al., 1995a; Laminet et al., 1996). The measured dissoci-
ation rate constant (koff) is 2.7510–2 s–1 and the derived
association rate constant (kon) is 8.5104 M–1s–1. The
dissociation and association rate constants are ~10-fold
lower than those for high affinity SH2-peptide interactions
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(kon, 1105 to 2106 M–1s–1 and koff, ~0.1 s–1) (Panayotou
et al., 1993; Ladbury et al., 1995).
Overall structure and peptide binding mode
The structures of two complexes of the X11 PTB domain
and two peptides (10 and 14 residues long, respectively)
from the APP cytoplasmic region have been determined
to nominal resolutions of 2.3 and 2.5 Å, respectively.
Multiwavelength anomalous diffraction (MAD) experi-
ments (Hendrickson, 1991) were used to provide independ-
ent phase information. Crystals of X11 complexed to
either peptide are in the tetragonal space group (P41212),
with cell dimensions of a  74.4/74.6 Å and c  157.1/
155.4 Å, for the 10/14 residue peptides, respectively. The
R-values are 21.2% (free R  30.3%) and 21.0% (30.3%)
for 10 residue and 14 residue peptide complexes, respect-
ively. With respect to the tyrosine residue of the NPxY
motif, which is denoted residue 0, the short peptide runs
from –6 to 3, while the long peptide runs from –8 to
3 (residues 4 and 5 are disordered). Due to the
higher resolution of the structure of the 10 residue peptide
complex, the analysis is based mainly on that structure.
There are two crystallographically independent X11/APP
peptide complexes in the asymmetric unit and they are
very similar (r.m.s. deviation of 0.94 Å for all Cα
atoms), except for certain loops. However, there are subtle
differences in terms of the detailed peptide interactions
between these two complexes, indicating a certain degree
of flexibility in the interface (see below).
Like the Shc and the IRS-1 PTB domains, the X11
PTB domain contains a ‘PH-fold’ first seen in the pleckstrin
homology domain (Macias et al., 1994). The PH fold
consists of a central β-sandwich structure and a C-terminal
α-helix (α2; Figure 1A) (Lemmon et al., 1996). In X11,
as in Shc (Zhou et al., 1995b), a large insertion between
two strands (β1 and β2) results in the formation of an
additional strand (β1) and an α helix (α1). This insertion,
which is not seen in the IRS-1 PTB domain, plays a role
in recognition of the peptide ligand. While the β1 strand
forms part of the β-sandwich on the edge that is opposite
to the peptide binding site, the α1 helix packs against one
face of the β-sheets. The N-terminal tip of helix α1
together with the β1/α1 loop flank the bound peptide on
one side, with helix α2 on the other side. The X11 PTB
domain contains a unique insertion of 20 residues in the
β6/β7 loop with respect to Shc. This large loop is located
near the tyrosine residue of the NPxY motif of the peptide
ligand (Figure 1A). However, it mediates few interactions
with the bound peptide and is mostly disordered in the
structure.
The APP peptide binds to the X11 PTB domain by
forming an anti-parallel hydrogen bonding interaction with
strand β5 of the PTB domain, thus becoming incorporated
into the β-sandwich that is the structural core of the domain
(Figures 1A and 3). Five peptide residues (residues –3
to –7, see Figure 3 for the numbering of peptide residues)
N-terminal to the NPxY motif are involved in the antiparal-
lel β-strand interaction. The NPTY motif of the bound
peptide adopts a β-turn conformation, capping the β-strand
of the peptide (Figure 1B). The peptide lies alongside
helix α2 in an antiparallel orientation, and the peptide
binding mode in X11 is similar to that seen in the Shc
and the IRS-1 structures (Zhou et al., 1995b; Eck et al.,
X11 PTB domain
Fig. 1. (A) Ribbon representation of the structure of the X11 PTB domain in complex with the 14 residue APP peptide. The core structure of the
X11 PTB domain resembles the ‘PH’ fold that consists of a β-sandwich (colored in light and dark green) and the C-terminal helix (α2; in yellow).
With respect to the PH fold and the IRS-1 PTB domains, X11 PTB domain contains a insertion that forms helix α1 and strand β1 (colored in blue).
The APP peptide (colored in orange) forms an anti-parallel β-strand with the β5 strand of the X11 PTB. Also shown are the sidechains of the
tyrosine (0; in pink) and the two C-terminal phenylalalines (2 and 3; in white) of the peptide. Residues 4 and 5 of the peptide are
disordered and not shown. Two missing loops (α1-β2 and β6-β7) are indicated by dashed lines. (B) Stereodiagram of the interactions between the
X11 PTB domain and the APP peptide. The X11 PTB domain is in a ribbon-representation, with sidechains colored in white. The peptide is shown
in ball-and-stick representation with carbons, oxygens and nitrogens coloured yellow, red and blue. Sidechains of the PTB domain are labelled as
follows: a, Phe486; b, Tyr483; c, Phe479; d, Gly476; e, Ala472; f, Gln473; g, Asp421; h, Ile419; i, Tyr418, j, Ser417; k, Gln358; l, Met354;
m, Gln356; n, Arg353; o, Ser344. The sidechain of Lys(1) of the peptide is removed for clarity. Figures are generated using MOLSCRIPT
(Kraulis, 1991) and Raster3D (Bacon and Anderson, 1988).
1996). Upon aligning the structures of the X11 with the
IRS-1 and Shc PTB domains (excluding the peptide from
the calculation), peptide residues containing the NPxY
motif and the residues N-terminal to it are essentially
superimposable (r.m.s. deviation 1.5/1.9 Å for the peptide
backbone of Shc/IRS-1 complexes, respectively). How-
ever, a unique aspect of the X11-peptide interaction is the
formation of a 310 helix by the C-terminal residues of the
peptide, with additional interactions with the PTB domain
(discussed below).
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Interactions with the NPxY motif
High-affinity peptides for PTB domains typically contain
an NPxY motif (usually phosphorylated on tyrosine) (Zhou
et al., 1995c) that has been shown to adopt a β-turn
conformation in solution even in the absence of the PTB
domains (Trub et al., 1995). In the three currently available
PTB structures (Shc, IRS-1, and X11), the NPxY motif
(phosphorylated in Shc and IRS-1, unphosphorylated in
X11) adopts a type I β-turn conformation when bound to
the PTB domains. The Asn residue of the -3 position of
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the NPxY motif has a conserved structural role for
stabilizing the β-turn conformation (Zhou et al., 1995b;
Eck et al., 1996). The carboxamide oxygen of the Asn(–3)
sidechain forms an intramolecular hydrogen bond with
the backbone amide group of the peptide residue at the
-1 position (Figure 3). The amino group of the Asn
sidechain is hydrogen bonded to the carbonyl groups of
Leu413 and Ile416 of the X11 PTB domain. Asn(–3), and
hence the β-turn conformation, appears to be the most
important determinant for interaction with the PTB
domains. A similar hydrogen bonding pattern was observed
in the structure of the IRS-1/peptide complex (Eck et al.,
1996) and is expected to be conserved in other PTB/
NPxY peptide interactions as well. Pro(–2) also plays a
role in stabilizing the β-turn conformation of the peptide
ligand; however, its importance varies. Replacing Pro(–2)
with Ala decreases the binding affinity to the Shc PTB
domain up to 50-fold, depending on the sequence contexts
of the peptide (Wolf et al., 1995; Laminet et al., 1996;
Mandiyan et al., 1996). In the X11 structure, the pyrrolid-
ine ring of Pro(–2) packs against the aromatic ring of
Tyr483 (from helix α2; Figures 1B and 3) while similar
hydrophobic interactions are provided by the aliphatic
portion of the Arg258 sidechain in the IRS-1 PTB domain
(Eck et al., 1996).
In the X11/APP peptide structure, the peptide is unphos-
phorylated. Despite the lack of a phosphate group, Tyr(0)
at the tip of the β-turn assumes a conformation that is
almost identical to that of the bound phosphotyrosine
residue observed in the IRS-1 and the Shc structures. As
in Shc (Zhou et al., 1995b), the aromatic ring of Tyr(0)
forms hydrophobic interactions with the Cβ atom of
Ser417 (Figures 1B and 3), while similar interactions are
mediated by Arg212 in the IRS-1/peptide structure (Eck
et al., 1996). Apart from this, no other specific interactions
for this tyrosine residue are observed. In particular, posit-
ively charged residues (Lys346, Arg431, Arg432, Arg433
and Arg353) in the general vicinity of the tyrosine hydroxyl
group are mostly disordered in the structure (Figure 5A).
Interestingly, Tyr(0) is not critical for the recognition of
the peptide, since replacing this residue with Ala results
in no significant loss of binding affinity (Borg et al., 1996).
The C-terminal specificity
In general, the peptide residues N-terminal to the NPxY
motif are considered to be the primary determinants of
the binding specificity of the PTB domains (Zhou et al.,
1995b, 1996; Eck et al., 1996). However, in X11 the
C-terminal residues (Phe 2 and 3) of the APP peptide
contribute positively to binding affinity. Mutation of either
Phe 2 or 3 to Ala separately decreases the binding
affinity by 10-fold (Table I). Residues 1 to 3 are in a
310 helical conformation and the aromatic rings of Phe
2 and 3 of the APP peptide pack against a hydrophobic
surface that is formed by a number of residues contributed
by helix α2 (Figures 1B and 5A). This helix is longer by
three turns with respect to Shc. As a result of these
additional interactions, the total surface area that is buried
between the APP peptide and the X11 PTB domain is
~2000 Å2, which is somewhat larger than those for Shc
and IRS-1 structures (~1800 and ~1300 Å2, respectively).
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Fig. 2. Molecular surface of the X11/APP peptide complex, calculated
with the peptide removed and displayed using GRASP (Nicholls et al.,
1991). The surface is colored according to the surface curvature
calculated in the absence of peptide. The peptide (backbone shown as
a blue tube) binds to a deep groove on the surface of the PTB domain.
Important sidechains in the X11 PTB domain are labeled as in
Figure 1B.
The N-terminal specificity
The APP peptide fits snugly into a groove on the peptide
binding surface of the X11 PTB domain (Figure 2). The
floor of the groove is formed by strand β5, which is part
of the β-sandwich and engages in antiparallel hydrogen
bonding interactions with peptide residues –4 to –8.
Alternate sidechains of the peptide [Asn(–3), Tyr(–5), and
Asn(–7)] interact with helix α2 (Figures 1B and 2). The
other sidechains [Glu(–4), Gly(–6) and Gln(–8)] point
toward strand β5 and helix α1. Two residues [Asn(–7)
and Gln(–8)] of the APP peptide appear to be important
for optimal binding, since removal of these two residues
decreases the binding affinity by 10-fold (as judged by
comparing the affinities of 14 residue and 10 residue APP
peptides). In addition to the backbone hydrogen bonding,
the sidechain of Asn(–7) also forms hydrogen bonds with
the sidechains of Asp 421 and Gln 469 (of X11) (Figure
1B). The polar nature of the peptide residue at position
–7 in APP peptide is in contrast to high affinity peptides
for Shc and IRS-1, which tend to contain hydrophobic
residues at this position (Wolf et al., 1995).
The X11 PTB domain also has selectivity for two other
peptide residues: Tyr(–5) and Glu(–4). Mutation of Tyr(–5)
to Gly abolishes the binding of APP to X11 (Borg et al.,
1996). The aromatic ring of Tyr(–5) packs against the Cα
atom of Gly476 and the sidechains of Ala472 and Ile419
(of X11) (Figures 1B and 2). The hydrophobic nature of
the Tyr(–5)-binding site suggests that the X11 PTB domain
might select for large hydrophobic amino acid at position
–5. Such a preference has been described for the Shc PTB
domain (Trub et al., 1995; Laminet et al., 1996; van der
Geer et al., 1996). Hydrogen bonding between the
hydroxyl group of the Tyr(–5) and the sidechain of Gln473
(of X11) was observed in one of the two complexes in
the asymmetric unit of the crystal (but not in the other
complex), implying that this interaction is dispensable.
X11 PTB domain
Fig. 3. Schematic depiction of contacts between the APP peptide and
the X11 PTB domain. The β strands are shaded green and orange for
the PTB domain and the peptide, respectively. Hydrogen bonds are
shown as dotted lines, and the distance between the atom attached to
the donor hydrogen and the acceptor is shown (in Å) for the
10-residue (above the lines) and the 14-residue (in parentheses, below
the lines) peptide complexes.
Replacing Glu(–4) with Ala reduces binding affinity by
5-fold (Table I). In the structure, the Glu(–4) sidechain
forms a salt bridge with Arg353 (of X11) which in turn
is held in position by hydrogen bonds with sidechains of
Gln356 and Ser344 (of X11) (Figure 1B). Arg353 is
mostly buried upon ligand binding. Selectivity for an
acidic residue at position –4 has been described for the
Shc PTB domain also (Laminet et al., 1996). Finally, the
selectivity for a glycine at position –6 is suggested by the
present structure. Met354 and Tyr418 (of X11) form
hydrophobic interactions with the Cα atom of Gly(–6)
(Figures 1B and 2). Given these steric constraints, this




The discovery of PTB domains originated from their
ability to bind to phosphorylated tyrosine residues in
signaling proteins, but with sequence specificity that is
fundamentally distinct from that of the SH2 domains
(Kavanaugh and Williams, 1994). Subsequent structural
analyses of phospho-peptide complexes of the Shc (Zhou
et al., 1995b) and IRS-1 (Zhou et al., 1996) PTB domains
showed that the architecture of these domains is related
to that of the PH domains, but not to that of SH2 domains.
Significantly, the recognition of phosphotyrosine residues
by PTB domains relies on basic residues in the domain
that are not conserved (Figure 4). The binding site for the
phosphotyrosine residue lies on the edge of the domain,
and the positively charged sidechains that interact with
the phosphate group are exposed to solvent (Zhou et al.,
1995b, 1996; Eck et al., 1996) (Figure 5A).
In this study we show that the recognition of the
unphosphorylated form of the APP peptide by the X11
PTB domain occurs by a mechanism that is essentially
the same as that utilized by the Shc and IRS-1 PTB
domains to bind to phosphorylated targets. The critical
elements of the recognition are the β-turn formed by the
NPxY motif and the incorporation of the peptide into a
β-sheet of the PTB domain. A striking feature of the X11/
APP peptide complex is that the unphosphorylated tyrosine
residue of the NPxY motif is bound in virtually the
same conformation as is seen for the corresponding
phosphotyrosine residue in Shc and IRS-1.
Quantitative binding studies demonstrate that addition
of a phosphate group to the tyrosine residue of the APP
peptide does not significantly change the binding affinity
for the X11 PTB domain (Table I). Several charged
residues that are in the vicinity of the tyrosine hydroxyl
group are potentially available to coordinate the phosphate
group in the phosphorylated form of APP (Figure 5A),
but clearly they do so with no net stabilization of the
complex. This is in contrast to the situation for Shc and
IRS-1, each of which also has a constellation of positively
charged residues at the phosphotyrosine-binding site. Shc
and IRS-1, however, have been shown to clearly discrimin-
ate between phosphorylated and unphosphorylated targets
(Zhou et al., 1995b, 1996). It thus appears that different
PTB domains have evolved different requirements for
phosphorylation of the tyrosine of the NPxY motif in
their targets.
The binding specificity of well characterized SH2
domains, on the other hand, appears to be restricted quite
sharply to phosphorylated peptides. In contrast to the PTB
domains, which bind tightly to their peptide targets by
extensive hydrogen bonding and packing interactions, the
SH2 domains have relatively limited interactions with
their target peptides (Kuriyan and Cowburn, 1997). Con-
sequently, the phosphotyrosine residue provides the major
anchor point for the peptide to the SH2 domain. A
comparison of the phosphotyrosine-binding sites of PTB
and SH2 domains is revealing in terms of suggesting why
phosphorylation of the target is dispensable in the case of
certain PTB domains, but is required in the case of the
SH2 domains. In the SH2 domains, a strictly conserved
residue Arg175 (βB5 in the SH2 notation) rises up from
the interior of the domain into a position where it can
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Fig. 4. Sequence alignment of PTB and PH domains. The secondary structure elements of the X11 PTB domain (residues 324 to 491) are boxed and
are shown schematically as colored arrows (for β-strand) and cylinders (for α-helix) above the sequence. The secondary structure elements for Shc
(Zhou et al., 1995b), IRS-1 (Eck et al., 1996) and two PH domains (Macias et al., 1994; Lemmon et al., 1996) are indicated in color. The basic
residues in the vicinity of tyrosine 0 of the peptide in X11 as well as those residues in IRS-1 and Shc that coordinate the phosphotyrosine are
colored red.
Fig. 5. Comparison of phosphotyrosine/tyrosine-binding sites of the X11 PTB domain and the Src SH2 domain. (A) Molecular surface of the X11
PTB domain, showing the binding site for the tyrosine (0) and the C-terminal region of the peptide. The polypeptide backbones of the bound
peptide and the X11 PTB domain are shown in red and blue tubes, respectively. Also shown are three basic residues (Lys 346, Arg431 and Arg432;
removed from surface calculation) of the X11 PTB domain that are potentially involved in phosphotyrosine-binding. The sidechains of Phe(2) and
Phe(3) of the peptide (colored in yellow) pack against the sidechains of Tyr483 and Phe 486 of the X11 PTB domain (colored in gold).
(B) Molecular surface of an unliganded Src SH2 domain (Waksman et al., 1993) showing the deeply buried ArgβB5 sidechain (not included in
surface calculation). For reference, the structure of a high affinity phosphopeptide is also shown (colored in gold), taken from the pYEEI/Src
complex (Waksman et al., 1993). The polypeptide backbone of the Src SH2 domain is shown in purple tubes.
engage two oxygens of the phosphate group of the ligand
(Figure 5B). This sidechain is quite buried in the SH2
structures. For example, in the uncomplexed Src SH2
structure (Waksman et al., 1993), the total surface accessib-
ility for ArgβB5 ranges from 2 to 6 Å2 for the four
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molecules in the crystallographic asymmetric unit (Figure
5B). This may be compared with a surface accessibility
of ~100 Å2 for Arg155 (αA2), an SH2 residue that engages
the phosphotyrosine from the surface. Analysis of the
structures of other uncomplexed SH2 domains, such as
X11 PTB domain
that of Syp/SH-PTP2 (Lee et al., 1994), reveals that the
buried nature of ArgβB5 is a conserved feature of the SH2
architecture (the solvent accessible surface for ArgβB5 is
~11 Å2 in SH-PTP2).
The burial of ArgβB5 in the SH2 structure, with limited
hydrogen bonding partners, is likely to have a significant
energetic penalty (Honig and Nicholls, 1995) and is
probably a critical architectural feature that then demands
that the ligand be phosphorylated in order to neutralize
the residue. In X11, basic residues that are in a position
to potentially interact with the phosphate group of phos-
phorylated ligands are all on the surface, and the lack of
stabilization of phosphorylated versus non-phosphorylated
APP peptide is likely to be a consequence of an unfavorable
desolvation energy for these sidechains. However, the
situation for PTB domains is clearly subtle, since the Shc
and IRS-1 PTB domains do bind much more strongly to
phosphorylated peptides than they do to nonphosphoryl-
ated ones (Kavanaugh and Williams, 1994; Batzer et al.,
1995b; Trub et al., 1995; Wolf et al., 1995). As in X11,
in the Shc and IRS-1 PTB the charged sidechains that
interact with the phosphotyrosine are solvent-accessible
and on the surface. The net stabilization of phosphorylated
peptides in this case must be the result of particularly
favorable geometries of interaction, an issue that will be
of interest to investigate further.
Sequence-specific recognition of peptides by the X11
PTB domain involves a number of residues distributed
over a relatively long region (10 to 13 residues) of the
peptide ligands. The differences in binding specificity
between X11 and the other characterized PTB domains
indicate that the PTB domains are capable of mediating
a broad spectrum of sequence-specific interactions. In
particular, our finding that C-terminal specificity can also
be a feature of PTB interactions further extends the
specificity of the PTB domain. Thus, the overlapping
specificity between Shc and IRS-1 PTB domains likely
reflects their shared biological functions in targeting com-
mon growth factor receptors instead of a limited repertoire
of the PTB-mediated interactions.
The understanding of the biological function of the
X11/β-APP interaction has been impeded by our limited
knowledge of these two proteins. While β-APP appears
to play a role in learning processes through an unknown
mechanism (Muller et al., 1994), there has been no known
function assigned to X11. However, the measured high
specificity and high affinity as well as the conserved
peptide binding mode observed in the X11/APP peptide
structure suggests that the interaction might be relevant.
Moreover, elimination of the X11 PTB domain binding
site (sequence YENPTY) on APP severely diminished
APP internalization and decreased the production of
amyloidogenic Aβ peptide (Koo and Squazzo, 1994). The
PTB domain of X11 appears to be solely responsible for its
interaction with β-APP, since no enhanced or cooperative
binding to β-APP was observed for the full-length X11
protein (J.-P.Borg and B.Margolis, unpublished data). The
present study reveals the critical determinants for X11/β-
APP interactions. Such information should facilitate fur-
ther dissection of physiological functions of β-APP as
well as the pathology of Alzheimer’s disease.
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Materials and methods
Protein expression and purification
The X11 PTB domain (residues 324–504) was amplified from a human
fetal brain cDNA library (Stratagene) by PCR. The amplified fragment
was cloned into a PET3a vector so that the gene for the PTB domain
was under the control of a T7 promoter. The complete DNA sequence
of the X11 PTB domain was confirmed by dideoxy sequencing. The
X11 PTB domain protein was expressed in Escherichia coli (BL21
strain) and was purified by passing through a Q-Sepharose and size
exclusion chromatography (yielding 50 mg of purified protein per liter
of cell culture). Se-methionine (Se-Met)-labeled protein was expressed
(Hendrickson et al., 1990) and purified using similar procedures as for
the native protein. The identity of the protein was confirmed by
N-terminal amino acid sequencing and mass spectroscopic analysis.
An Fmoc-based strategy in conjunction with standard side chain
protecting groups was applied for peptide synthesis. Fmoc-L-tyrosine
(PO3H2)-OH was used for incorporation of phosphotyrosine (Batzer
et al., 1995a). Peptides were purified by ether precipitation and reverse
phase HPLC.
Peptide binding studies
Surface plasmon resonance (SPR) measurements were carried out on a
BIAcore Biosensor instrument (BIAcore 1000, Pharmacia Biosensor).
The wild-type APP 14 residue peptide was cross-linked to a CM5 sensor
chip by the amine coupling method (Felder et al., 1993). Various
concentrations (0.1–10 μM) of the X11 PTB domain were injected onto
the cross-linked surface and the association and dissociation responses
were followed. The same concentrations of the protein were also injected
onto a non-cross-linked surface to measure the background signals,
which were then subtracted from the binding responses. All binding
experiments were performed at 25°C with a flow rate of 10 μl/min in
HBS buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 1 mM EDTA,
0.05% surfactant P20 and 1 mM DTT). The binding properties of various
mutant and phosphorylated peptides were followed by competition
experiments. Here, various concentrations of peptides were pre-mixed
with a given concentration of PTB domain protein and their binding
responses to the cross-linked surface were evaluated. All data obtained
were the average of at least four independent experiments. The kinetic
parameters were evaluated using the BIAevaluation software
(Pharmacia).
Crystallization and data collection
The X11 PTB domain protein was mixed with excess peptide (peptide:
protein ratio of 1.5 or greater) in 10 mM Hepes (pH 7.5), 150 mM
NaCl, and 1 mM DTT. Crystallization conditions were scanned using
the hanging-drop method. Crystals of the complex were obtained in
several days at 21°C with ammonium sulfate as the precipitant (1.4 M
ammonium sulfate, pH 6.5, 100 mM MES, 100 mM NaCl, for the 10-
residue peptide complex; and 1.8 M ammonium sulfate, pH 6.5, 100 mM
Mes, for the 14-residue peptide complex). The crystals belong to the
tetragonal space group (P41212, a  b  74.4/74.6 Å, c  157.1/
155.4 Å for the 10/14 residue peptide complexes, respectively) and
diffract to beyond 2.5 Å using an in-house X-ray source. Crystals of the
Se-Met labeled protein diffract X-rays more strongly than those of native
protein, and the Se-Met crystals were used for all the structural analysis.
All diffraction data were collected from crystals cooled to 100 K after
cryoprotection in 5–30% glycerol. X-ray data for MIR analysis were
collected on a Rigaku RAXIS IIC area detector mounted on a Rigaku
RU200 X-ray generator (Molecular Structure Corporation, USA). Crys-
tals were derivatized before data collection by soaking in 15 mM
trimethyl lead acetate for 24–36 h. MAD data were collected from a
single frozen crystal (10 residue peptide complex; Se-Met derivative) at
the National Synchrotron Light Source (Brookhaven Nation Laboratory)
using beamline 25. All data were processed using program DENZO
and SCALEPACK (Z.Otwinowski and W.Minor).
Phase determination
Crystals of the 10 residue peptide complex soaked in solutions containing
15 mM trimethyl lead acetate yielded a derivative and still retained high
resolution diffraction (2.5 Å). The positions of two bound lead atoms
were determined using the program SHELX-90 (Sheldrick, 1991). Heavy
atom parameters were then refined and initial phases were calculated for
two alternative space groups (P41212 and P43212) in combination with
two different heavy atom configurations, using the program MLPHARE
(Z.Otwinowski, unpublished program). The resulting SIRAS maps were
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Table II. Data collection and refinement statistics
Crystallographic analysis statistics: (for X11/10mer peptide complex)
Data set Resolution Reflections Completeness(%) Rmerge(%)a Risob Phasing
(Å) measured/unique overall/outer shell overall/outer shell power
SIRAS analysis
Se-Met 30–2.5 70368/15538 97.0/95.6 6.9/27.0
(Seleno-methionine, in-house X-ray source)
MePbAc 30–2.5 113378/16169 99.8/98.7 8.3/34.7 0.22 0.88
(trimethyl lead acetate, 2 sites, in-house X-ray source)
Overall SIRAS figure of merit 0.32 (20~2.7Å)
MAD analysis
Se-Met (13 sites, BNL synchrotron, Beamline X25)
λ1(0.9770Å) 30.0–2.6 117094/14337 99.6/97.4 8.3/26.6 (14.4 at 2.9Å) 0.0453
λ2(0.9793Å) 30.0–2.6 118270/14300 99.9/99.6 8.8/30.2 (15.6 at 2.9Å) 0.0349
λ3(0.9797Å) 30.0–2.6 118133/14326 99.3/94.3 8.5/27.6 (14.5 at 2.9Å) –
Overall MAD figure of merit 0.66 (15~2.9Å)
Data sets used for refinements
X-11/10mer peptide (in-house X-ray source)
Se-Met 30–2.3 69525/18927 92.4/80.0 8.3/22.9
X-11/14mer peptide (in-house X-ray source)
Se-Met 30–2.4 97157/17790 99.3/99.2 5.4/30.2
Refinement statistics
X11/APP peptide(14mer) X11/APP peptide (10mer)
Resolution (Å) 6.0–2.5 6.0–2.3
Completeness (%) (|F|2.0 σ|F|) 82.7 69.0
R-factor (Free Rc) (%) 21.2 (30.3) 21.0 (30.3)
Completeness (%) (|F|0 σ|F|) 93.4 91.3
R-factor (Free R)c,d (%) 23.2 (32.5) 24.5 (34.4)
Number of non-hydrogen atoms 2221 2155
Number of residues 285 (390) 266 (384)
Number of waters 161 215
R.m.s.d. bond lengths (Å) 0.010 0.010
R.m.s.d. bond angles (Å) 1.8 1.8
R.m.s.d. B value(bonds) (Å2) 1.30 1.54
R.m.s.d. B value(angles) (Å2) 1.65 1.81
aRmerge  100Σh Σi |Ih,i – Ih| /Σh Σi Ih,i
bRiso  Σh|Fnat,h – Fderiv,h|/Σh Fnat,h. For MAD analysis, Riso is calculated between data at two wavelengths. Wavelength 2 is used as reference data
set (Fnat) in this calculation and Fderiv refers to data at another wavelength.
cFree R-factor was calculated using 10% of the data.
dNote that data with |F|  2σ|F| were not used in the refinement.
generally uninterpretable, consistent with the low value of figure of
merits (0.32). We therefore sought additional phase information.
A multiwavelength anomalous diffraction (MAD) experiment was
performed on the Se-Met derivative of the 10 residue peptide complex.
For MAD data collection, a single Se-Met crystal was mounted, after
flash freezing, with the c* axis approximately parallel to the spindle in
order to facilitate the data collection. The inverse beam method was
used to collect Bijvoet pairs of reflection. Data collection at three
wavelengths near the Se absorption edge (Table II) were recorded on a
Mar detector and beamline X25, National Synchrotron Light Source,
and processed with DENZO and SCALEPACK. The positions of 13 Se
atoms (out of a total 16 Se atoms) in the asymmetric unit were identified
by difference Fourier techniques using the phases calculated from the
lead derivative. Heavy atom parameters were then refined and phases
were calculated using the program MLPHARE (Z.Otwinowski) for two
alternative space groups (P41212 and P43212). Summary statistics from
the MAD phasing procedure are given in Table II. Using only MAD
data, phases calculated at 2.9 Å resolution with space group P41212
yielded an interpretable electron density map which was further improved
by solvent flattening and histogram matching, using SQUASH (Zhang
and Main, 1990) and information from the lead derivative was not
used further.
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Model building and refinement
A model accounting for 90% of the structure was built into the MAD
map using the program O (Jones et al., 1991) and was refined using
XPLOR (Brünger, 1988) without simulated annealing. The free R value
(Brünger, 1993) was used to monitor all stages of the refinement. The
asymmetric unit contains two X11 PTB/APP peptide complexes which
are very similar to each other. Although the noncrystallographic symmetry
was not explicitly used in the refinement processes, it provided a useful
check on the accurancy of the model. The resolution was later extended
to 2.3 Å using a data set collected in-house. Well-ordered solvent
molecules were included at this stage, and tightly restrained individual
isotropic B-factors were refined.
The statistics for data collection, phase determination and refinement
are given in Table II. The working R value is 21.0% using data between
6.0 to 2.3 Å and the free R value (10% of the data) is 30.3% for final
model using reflections with |F|/σ(|F|) 2.0. The current model includes
two complexes of X11 PTB/APP peptide (246 residues for two X11
PTB domains and 20 residues for APP peptides), and 215 water
molecules. No electron density is present for 14 residues in the α1/β2
loop, 23 residues in the β6/β7 loop and 16 residues at the C-terminus
of the first X11 PTB molecule, as well as for 7 residues at the N-terminus
in addition to 10 residues at the C-terminus of the second X11 PTB
X11 PTB domain
molecule. The average temperature factor for protein atoms is 35.6 Å2.
Although the two X11 PTB/APP peptide complexes are very similar,
certain details in the domain/peptide interfaces are slightly different
(see Results).
Crystals of the X11 PTB domains in complex with the 14 residue
APP peptides were also obtained, which belong to the same space group
as those of X11 PTB/10 residue APP peptide complexes. The positions
of two additional peptide residues at the N-terminus were identified by
difference Fourier techniques using phases calculated from the model
of the X11 PTB/10 residue peptide. The additional C-terminal residues
are poorly ordered. A model was refined at 2.5 Å resolution using a
data set collected in house. 285 residues and 161 water molecules were
included in the model. The working R value is 21.2% using data between
6.0 to 2.5 Å and the free R value (10% of the data) is 30.3% for final
model using reflections with F/σF 2.0. Both coordinate sets have been
deposited in the Brookhaven Protein Data Bank with identity codes 1x11
and 1aqc for the long and short peptides, respectively.
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